90Y-daclizumab

N/A

Report date: 2025/09/15 20:01:49

Base Information

Drug Name90Y-daclizumab

Drug Alias NameYttrium-90-labeled Daclizumab(90)Y-labeled daclizumab

ClassificationRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-IL2RA

TargetsInterleukin-2 receptor alpha chain

Therapy Area/IndicationsHodgkin Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsHodgkin Disease

Other Information

ATC CodeN/A